CD19 antibody-drug conjugates (ADC) such as coltuximab ravtansine (SAR3419) have shown tolerability but poor clinical response in patients with relapsed or refractory BCP-ALL [14]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.